The global radiopharmaceuticals market is witnessing strong growth due to increasing demand for precision diagnostics and targeted cancer therapies. According to a recent market analysis, the industry is valued at approximately USD 7.82 billion in 2026 and is projected to reach USD 13.78 billion by 2036, registering a CAGR of 5.48% during the forecast period.

Radiopharmaceuticals play a critical role in modern healthcare by enabling advanced diagnostic imaging and targeted therapeutic procedures across oncology, cardiology, neurology, and other medical specialties. The growing prevalence of cancer worldwide continues to drive adoption of PET and SPECT imaging technologies, while advancements in theranostics and personalized medicine are further expanding market opportunities.

Full Read: https://www.quintilereports.com/industry-report/1298-radiopharmaceuticals-market/

The report highlights Technetium-99m as the dominant radioisotope segment due to its widespread use in diagnostic imaging procedures. Meanwhile, isotopes such as Lutetium-177 and Gallium-68 are gaining traction because of their increasing application in targeted radionuclide therapies and precision oncology.

Regionally, North America remains the leading market owing to advanced nuclear medicine infrastructure and strong healthcare investments. East Asia is expectedq to emerge as the fastest-growing region, supported by rapid healthcare modernization and increasing oncology care demand in countries such as China and South Korea.

Key industry participants include Novartis, GE HealthCare, Bayer, Siemens Healthineers, and Lantheus Holdings. The market is expected to benefit from continued investments in isotope production, radioligand therapies, and nuclear medicine infrastructure worldwide.